August 17, 2019

Winnipeg
22° C, Partly cloudy

Full Forecast

Advertisement

Advertise With Us

Medical research sector thriving in province

BORIS MINKEVICH / WINNIPEG FREE PRESS</p><p>Bram Ramjiawan (left) and Grant Pierce say the St. Boniface Hospital Albrechtsen Research Centre has a number of promising projects underway.</p>

BORIS MINKEVICH / WINNIPEG FREE PRESS

Bram Ramjiawan (left) and Grant Pierce say the St. Boniface Hospital Albrechtsen Research Centre has a number of promising projects underway.

Hey there, time traveller!
This article was published 11/5/2016 (1193 days ago), so information in it may no longer be current.

The development of a medical research institution can be a tricky business unless there’s an unlimited source of capital to keep plowing into the enterprise.

The St. Boniface General Hospital does not have that kind of capital, but it’s picking up steam.

Last year, when Paul Albrechtsen donated another $5 million — on top of the $2 million he’d previously donated to St. Boniface — he became the most significant donor in the hospital’s 145-year history.

The St. Boniface Hospital Research Centre was renamed the St. Boniface Hospital Albrechtsen Research Centre (SBHARC), and the donation helped increase the the endowment fund from $15 million to more than $30 million and wiped out the last vestiges of the deficit the research centre has carried.

Get the full story:

Already have an account? Log in here »

Keep reading free:

Already have an account? Log in here »

Subscribers Log in below to continue reading,
not a subscriber? Create an account to start a 30 day free trial.

Log in Create your account

Your free trial has come to an end.

We hope you have enjoyed your trial! To continue reading, we recommend our Read Now Pay Later membership. Simply add a form of payment and pay only 27¢ per article.

For unlimited access to the best local, national, and international news and much more, try an All Access Digital subscription:

Thank you for supporting the journalism that our community needs!

Your free trial has come to an end.

We hope you have enjoyed your trial! To continue reading, we recommend our Read Now Pay Later membership. Simply add a form of payment and pay only 27¢ per article.

For unlimited access to the best local, national, and international news and much more, try an All Access Digital subscription:

Thank you for supporting the journalism that our community needs!

We hope you have enjoyed your free trial!

To continue reading, select a plan below:

All Access Digital

Introductory pricing*

99¢

per month

  • Unlimited online reading and commenting
  • Daily newspaper replica e-Edition
  • News Break - our award-winning iOS app
  • Exclusive perks & discounts
Continue

Read Now Pay Later

Pay

27¢

per article

  • Commitment-free
  • Cancel anytime
  • Only pay for what you read
  • Refunds available
Continue

*Introductory pricing schedule for 12 month: $0.99/month plus tax for first 3 months, $5.99/month for months 4 - 6, $10.99/month for months 7 - 9, $13.99/month for months 10 - 12. Standard All Access Digital rate of $16.99/month begins after first year.

We hope you have enjoyed your free trial!

To continue reading, select a plan below:

Read Now Pay Later

Pay

27¢

per article

  • Commitment-free
  • Cancel anytime
  • Only pay for what you read
  • Refunds available
Continue

All Access Digital

Introductory pricing*

99¢

per month

  • Unlimited online reading and commenting
  • Daily newspaper replica e-Edition
  • News Break - our award-winning iOS app
  • Exclusive perks & discounts
Continue

Mon to Sat Delivery

Pay

$34.36

per month

  • Includes all benefits of All Access Digital
  • 6-day delivery of our award-winning newspaper
Continue

*Introductory pricing schedule for 12 month: $0.99/month plus tax for first 3 months, $5.99/month for months 4 - 6, $10.99/month for months 7 - 9, $13.99/month for months 10 - 12. Standard All Access Digital rate of $16.99/month begins after first year.

We hope you have enjoyed your free trial!

To continue reading, select a plan below:

All Access Digital

Introductory pricing*

99¢

per month

  • Unlimited online reading and commenting
  • Daily newspaper replica e-Edition
  • News Break - our award-winning iOS app
  • Exclusive perks & discounts
Continue

Read Now Pay Later

Pay

27¢

per article

  • Commitment-free
  • Cancel anytime
  • Only pay for what you read
  • Refunds available
Continue

*Introductory pricing schedule for 12 month: $0.99/month plus tax for first 3 months, $5.99/month for months 4 - 6, $10.99/month for months 7 - 9, $13.99/month for months 10 - 12. Standard All Access Digital rate of $16.99/month begins after first year.

We hope you have enjoyed your free trial!

To continue reading, select a plan below:

Read Now Pay Later

Pay

27¢

per article

  • Commitment-free
  • Cancel anytime
  • Only pay for what you read
  • Refunds available
Continue

All Access Digital

Introductory pricing*

99¢

per month

  • Unlimited online reading and commenting
  • Daily newspaper replica e-Edition
  • News Break - our award-winning iOS app
  • Exclusive perks & discounts
Continue

*Introductory pricing schedule for 12 month: $0.99/month plus tax for first 3 months, $5.99/month for months 4 - 6, $10.99/month for months 7 - 9, $13.99/month for months 10 - 12. Standard All Access Digital rate of $16.99/month begins after first year.

Hey there, time traveller!
This article was published 11/5/2016 (1193 days ago), so information in it may no longer be current.

The development of a medical research institution can be a tricky business unless there’s an unlimited source of capital to keep plowing into the enterprise.

The St. Boniface General Hospital does not have that kind of capital, but it’s picking up steam.

Last year, when Paul Albrechtsen donated another $5 million — on top of the $2 million he’d previously donated to St. Boniface — he became the most significant donor in the hospital’s 145-year history.

The St. Boniface Hospital Research Centre was renamed the St. Boniface Hospital Albrechtsen Research Centre (SBHARC), and the donation helped increase the the endowment fund from $15 million to more than $30 million and wiped out the last vestiges of the deficit the research centre has carried.

Grant Pierce, executive director of research for the past 11 years, was one of the original team of five principal investigators that helped start the centre back in the late ‘80s.

"Now, this is a mature, fully occupied research facility with 250 full-time researchers and an operating budget of about $15 million annually," he said.

Researchers at SBHARC have a better-than-average track record of success in funding applications and have established a number of successful partnerships with private-sector funders such as the Heart and Stroke Foundation.

In the intervening years, the I.H. Asper Clinical Research Institute has also filled with additional research, patient care and a busy clinical-research and clinical-trial enterprise headed by Bram Ramjiawan, who is one of the leading authorities on regulatory requirements of clinical trials and who sits on the biggest European and American panels.

Arguably SBHARC’s most famous discovery so far was Pierce’s own work, originally published in 2012, that showed that 30 grams of flaxseed each day for six months can lower blood pressure and which could result in about a 50 per cent reduction of strokes and 30 per cent fewer heart attacks. (The next trial is about to get underway, giving flaxseed to people with high blood pressure who are not already on hypertension medicine.)

But Pierce points to the centre’s track record of success in commercializing research — three out of 10 projects were spun off as independent companies are still operating — as well as the pipeline of therapeutics that are in varying stages of development as proof of the centre’s contributions and impact in the market.

"We now have three more that look pretty exciting that are not at the spin-off stage yet, but at various stages of patenting," Pierce said.

One of them has the potential to be the first drug ever to treat diabetic neuropathy, nerve damage that can occur in feet and legs of diabetics. Patients lose the sense of pain in the region and are then to susceptible to infections that often lead to amputations.

Dr. Paul Fernyhough, director of the division of neurodegenerative disorders at the research centre, has patented a compound that may cause nerve re-generation, formed a company called WinSanTor along with colleagues in San Diego and Toronto and is in phase II clinical trials.

"It is an old drug that is being repurposed," said Ramjiawan. "There are drugs that treat the needle pain sensation some diabetics gets. But this is different. This is for nerve regrowth."

Another therapeutic drug treatment to treat fibrosis is being led by Michael Czubryt, principal investigator in molecular pathophysiology, is at an earlier stage of development.

"I am convinced we are sitting on three or four things that could be worth billions. But it is the age-old challenge — how to make sure if and when it happens we don’t just hand it all over to Big Pharma," said Chuck LeFleche, CEO of the St. Boniface Hospital Foundation.

That’s why SBHARC’s model that includes the continuum from basic science to clinical trials — from bench to bedside — is so promising. It allows the institution to retain control of the innovation further through development.

That and several other elements have helped make SBHARC the top-ranked research intensive hospital in Western Canada by Research Infosource and the 29th largest research facility in the country, second only to the Winnipeg Regional Health Authority in Manitoba.

Christina Weise, the CEO of Research Manitoba, said there are other research facilities that do it, but the one at St. Boniface has put together the right mix of relevant research with the attendant funding support of the hospital, the University of Manitoba (virtually all the researchers are faculty members of the U of M) the province and the national research funding bodies.

"It is not a coincidence that the cardiac program within the WHRA exists at St. Boniface and that they have an associated biomedical research group that sometimes works quite closely with the clinicians," she said. "That is a really important thing that research centres do."

martin.cash@freepress.mb.ca

 

 

Martin Cash

Martin Cash
Reporter

Martin Cash has been writing a column and business news at the Free Press since 1989. Over those years he’s written through a number of business cycles and the rise and fall (and rise) in fortunes of many local businesses.

Read full biography

Advertisement

Advertise With Us

You can comment on most stories on The Winnipeg Free Press website. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or digital subscriber to join the conversation and give your feedback.

Have Your Say

Have Your Say

Comments are open to The Winnipeg Free Press print or digital subscribers only. why?

Have Your Say

Comments are open to The Winnipeg Free Press Subscribers only. why?

By submitting your comment, you agree to abide by our Community Standards and Moderation Policy. These guidelines were revised effective February 27, 2019. Have a question about our comment forum? Check our frequently asked questions.

Advertisement

Advertise With Us